Thank you for your thoughtful answer. I would have them explore strategic alternatives, such as selling the company to a major pharma. The pace at which this company is moving indicates a conservative strategy based, no doubt, on the need to conserve capital. Making the substantial resources of a major pharma company available to them could significantly increase the speed with which they will obtain their goals for expansion. It is currently taking too long for this company to become profitable.
What would you propose they do? They have set reasonable goals that add value to the Co. (i.e., secure medicare coverage of prostate, launch liquid biopsy, etc.). They deal in an industry that requires proof of the value of the product, so they must maintain the scientific demeanor. They have done a few investor conferences and ASHTO, so I don't fault them. There is a site that ranks biotechs on whether they are unfriendly shareholder (due to option dilution, secondaries etc.). I don't remember GHDX being high on the list in a negative context (i.e., acting in a manner that was not consistent with shareholder interests).
Fact of the matter is that if GHDX executes on their strategic initiatives the share price will follow. They are balancing the need to build out a urology and European sales force with shareholder desires to maximize profitability.
That said, I sold off about half my shares in January due to macro-market concerns for all US stocks. I've started adding back shares slowly.
Do you think the management of this company gives a wit about its shareholders. It is more like a group of academics, happily pursuing their research, hoping some day to hit it big. Expanding their markets to solidify support for their salaries, but somewhere along the line they forgot about the shareholders.
Think that might have something to do with the performance of the stock?